Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Hypertension

Volumn 63, Issue 3, 2014, Pages 507-513

  Welsh, Paul ^a   Poulter, Neil R ^b   Chang, Choon L ^b   Sever, Peter S ^b   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

antihypertensive agents; cardiovascular diseases; hypertension; natriuretic peptides; risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; SCANDINAVIA; TIME; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HYPERTENSION; NATRIURETIC PEPTIDES; RISK FACTORS;

AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREVALENCE; PROGNOSIS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCANDINAVIA; TIME FACTORS;

EID: 84894470881     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02204     Document Type: Article

References (32)

1. Nadir MA, Witham MD, Szwejkowski BR, Struthers AD. Meta-Analysis of B-Type natriuretic peptide's ability to identify stress induced myocardial ischemia. Am J Cardiol. 2011;107:662-667.
2. Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17:81-96.
3. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105-1107.
4. Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N. N-Terminal pro-B-Type natriuretic peptide and the prediction of primary cardiovascular events: Results from 15-year follow-up of WOSCOPS. Eur Heart J. 2013;34:443-450.
5. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-Type natriuretic peptides and cardiovascular risk: Systematic review and meta-Analysis of 40 prospective studies. Circulation. 2009;120:2177-2187.
6. Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N. NT-pro BNP is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without preexisting cardiovascular disease. J Am Coll Cardiol. 2011;58:56-64.
7. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahloddddf B, Sever PS, Poulter NR. Prognostic significance of visit-To-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
8. Nakatsu T, Shinohata R, Mashima K, Yuki Y, Nishitani A, Toyonaga S, Ogawa H, Hirohata S, Usui S, Kusachi S. Use of plasma B-Type natriuretic peptide level to identify asymptomatic hypertensive patients with abnormal diurnal blood pressure variation profiles: Nondippers, extreme dippers, and risers. Hypertens Res. 2007;30:651-658.
9. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-Type cardiac natriuretic peptides in mild, stable heart failure. Circulation. 2006;113:977-985.
10. Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K, Woo KS. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: A double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J. 1995;74:502-507.
11. Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR. Effect of beta-blockade and ACE inhibition on B-Type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther. 2008;22:305-311.
12. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: Physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290:H17-H29.
13. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators. Evaluation of C-reactive protein prior to and on-Treatment as a predictor of benefit from atorvastatin: Observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012;33:486-494.
14. Sever PS, Dahloddddf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19:1139-1147.
15. Dahloddddf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.
16. O'Brien E, Gribbin C, Stanton A, Atkins N, Lyons S; Anglo-Scandinavian Cardiac Outcomes Trial. Left ventricular hypertrophy and silent ischaemia: A pilot study to examine the relationship in hypertensive patients. J Hum Hypertens. 2001;15(suppl 1):S75-S77.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44:837-845.
18. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
19. Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, Vincent M, Lantelme P. N-Terminal pro-brain natriuretic peptide: A powerful predictor of mortality in hypertension. Hypertension. 2011;57:702-709.
20. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60:960-968.
21. Struthers AD. A new approach to residual risk in treated hypertension-3P screening. Hypertension. 2013;62:236-239.
22. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-Terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174.
23. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt PR. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: A LIFE substudy. J Hypertens. 2005;23:1083-1090.
24. Davies J, Carr E, Band M, Morris A, Struthers A. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?. J Renin Angiotensin Aldosterone Syst. 2005;6:151-153.
25. B-Type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading (NCT01584518). http://clinicaltrials.gov/ct2/show/ NCT01584518. Accessed November 28, 2013.
26. Felker GM. Biomarkers as surrogate end points in heart failure trials. Heart Fail Clin. 2011;7:501-507.
27. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J; Heart Outcomes Prevention Evaluation (HOPE) Study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130-2131.
28. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
29. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment?. Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-2680.
30. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
31. Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators. Evaluation of C-reactive protein before and ontreatment as a predictor of benefit of atorvastatin: A cohort analysis from the anglo-scandinavian cardiac outcomes trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717-729.
32. Cauliez B, Guignery J, Marinier S, Mariau I, Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem. 2008;45(Pt 3):318-319.